Mikhail Blagosklonny’s Efforts towards Helping Cancer Patients and Finding a Way to Slow Aging

In 2015, the science journal Impact Journals published a report of the findings on the status of rejuvenating the body’s immunity using anti-aging drugs. The study which is the work of Mikhail Blagosklonny revealed that Everolimus could drastically improve immunity in aged people. The revelation surfaced in 2014 and instigated research on how humans can beat death’s timing by slowing the aging process. This investigation has scientists knocking on the door of immortality and has left people wondering what will be the primary cause of death after the alienation of the body’s degradation process. Visit ResearchGate to keep up to date with Mikhail’s latest work.

Mikhail Blagosklonny is a dedicated scientist with an inclination to develop cancer therapies and treatments among other minute topics. His researches cover ontogenesis, signal transduction, tumor suppression, drug resistance, selective cell protection, cell processes, apoptosis, and mitosis. One of Mikhail’s achievements is the conclusion that TOR signaling is a potential treatment of cancer and a remedy to aging. The study indicated that use of Rapamycin could firmly progress treatment of cancer and possibly eradicate excessive cell processes that accelerate aging. Mikhail’s works have earned him recognition as a leading advocate for cancer research and the development of Rapamycin.

Mikhail Blagosklonny additionally doubles as an avid writer for scientific journals and is the editor in chief of Cell Cycle and Oncotarget. He is an associate editor of Cancer Therapy and Biology, PLOS ONE, International Journal of Cancer, and the American Journal of Pathology. He sits on the editorial council of Cell Death and Differentiation. Mikhail has a total of 300 published research papers, book chapters, and reviews. He has outstanding interests in oncology, chemotherapy engineering, and cell cyclotherapy.

Mikhail Blagosklonny is a professor at the Roswell Park Cancer Institute who specializes in the study of oncology. He is an alumnus of First Pavlov State Medical University where he earned his degree in internal medicine. He also pursued his doctorate in experimental medicine and cardiology from the same institution. In 2002, Mikhail became an associate professor of medicine at the New York Medical College located in Valhalla. After leaving the school, he joined Ordway Research Institute as a senior scientist. In 2009, he joined Roswell Park Institute where he conducts he researches in anti-aging medicine, cancer therapeutics, targeted cancer treatments and biogerontology. Follow Mikhail on Google Scholar

Mikhail who is known by his staff as Misha has earned a name as a prominent part of the movement geared towards finding a cure for cancer. The senior vice president of the department of basic science ate Roswell and chairman of the department handling cell stress biology, Andrei V. Gudkov, stated that Misha is a vital part of the institution. He explained that Mikhail’ extensive experience and ground-breaking discoveries would help Roswell develop methods of applying cancer therapies that simultaneously protect healthy cells. He added to note that Roswell has world-class techs and a competitive team that will complement Misha’s talents. Mikhail Blagosklonny explained that he gains innumerable satisfaction in his line of work because he gets to develop solutions for aching needs of humanity. He said that he has the ambition to lessen the pains caused by diseases and ultimately alienate their existence.